Not enough data
Martin David Harp's coverage predominantly focuses on ophthalmology, eye care, and FDA approvals within the healthcare and pharmaceutical industry. His articles often cite data and include press releases or announcements from relevant companies or organizations in this field.
Based on his focus, Martin would likely value pitches that offer insights into groundbreaking medical advances in ophthalmology, particularly those related to new treatments, technologies, or FDA approvals. Given the emphasis on citing data and expert commentary in his coverage attributes, he may be receptive to pitches featuring credible experts who can provide insightful analysis of the latest developments in these areas.
As a journalist with a national focus on Australia but covering international topics such as COVID-19 impact on ophthalmology education in the UK, it could be beneficial to tailor pitches by highlighting any relevance or implications for the Australian context when applicable.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Patipol Tiyajamorn, Martin David Harp, Hattie Hayes
At ARVO 2025, in Salt Lake City, Utah, Patipol Tiyajamorn, talked about his poster on using graph neural networks to identify fast glaucoma progressors solely using optic nerve head morphology at a single time point
At ARVO 2025, in Salt Lake City, Utah, Yuhua Zhang, PhD, talked about his presentation on in vivo imaging of retinal pigment epithelium metabolic function in age-related macular degeneration
By: Alex-Choi, Alex Choi, Martin David Harp, Hattie Hayes, Alfredo A. Sadun
MJH Life Sciences ® - Ophthalmology news, articles, and events. All rights reserved.
By: Alex Choi, Martin David Harp, Hattie Hayes
At ARVO 2025, in Salt Lake City, Utah, Alex Choi discussed his poster on APOE carrier genetic status and its relation to Alzheimer disease as well as changes of the retina that might reflect early signs leading to an earlier diagnosis of the disease
By: Martin David Harp, Hsin-Yu Yang, Hattie Hayes
At ARVO 2025, in Salt Lake City, Utah, Hsin-Yu Yang talked about the 9-month results from her study on the effectiveness of DIMS spectral lenses in myopic retardation for the pre-myopic preschoolers in Taiwan.
By: Martin David Harp
At ARVO 2025, in Salt Lake City, Utah, Steven Barnes, PhD, talked about his research on the OPA1 mutation in retinal ganglion cells'effect on the cell's electrical function.
By: Emily Kaiser Maharjan, Martin David Harp
Tryptyr, a TRPM8 receptor agonist, is FDA-approved for dry eye disease, enhancing tear production by stimulating corneal sensory nerves.
By: Hattie Hayes, Martin David Harp, Emma Lessieru
At ARVO 2025, in Salt Lake City, Utah, Emma Lessieru, MD, PhD, talked about her poster on retina extracellular vesicles, and the role that they play on diabetic retinopathy.
By: Martin David Harp
FDA noted that the US phase 2 trial may serve as 1 of the 2 pivotal trials required for NDA filing.
(833) 317-6278 